RCEL News and Press, Avita Medical Inc. From 09/14/25

VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical D...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVITA Medical, Inc. (“AVITA” or “the Company”) (NASDAQ: RCEL ) for violations of the securities laws. The investigation fo...

The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ:RCEL) investors concerning the Company’s possible violation of the federal securities laws or other unlawful business ...

2025-09-08 18:23:59 ET AVITA Medical, Inc. (RCEL) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT... Read the full article on Seeking Alpha For further details see: AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global...

Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin grafting More than $42,000 per patient cost savings, together with improved patient throughput, support operational ...

New York, New York--(Newsfile Corp. - August 28, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of AVITA Medical, Inc. ("AVITA Medical, Inc.") (NASDAQ: RCEL) concerning possible violations of federal securities laws. AVITA reported second quarter 2025 resu...

2025-08-26 08:03:18 ET This is my sixth article on regenerative medicine and wound care company AVITA Medical ( RCEL ); it follows most recently 03/2023's AVITA Medical: At A Crossroads ". In Crossroads, I rated Avita as a "Hold". In the interim its price has ebbed and flowe...

Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX) Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing...

VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corb...

2025-08-08 15:22:23 ET More on AVITA Medical AVITA Medical, Inc. (RCEL) Q2 2025 Earnings Call Transcript AVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet Challenges AVITA Medical GAAP EPS of -$0.38 misses by $0.12, revenue of $18.42M mis...